Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate

S. E. Holwell, P. A. Cooper, M. J. Thompson, George Pettit, J. W. Lippert, S. W. Martin, M. C. Bibby

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The combretastatins are derived from an African medicinal plant Combretum caffrum (Combretaceae). They have previously been shown to be potent inhibitors of microtubule assembly that cause marked haemorrhagic necrosis in murine subcutaneous tumors. Promising clinical trial results with combretastatin A-4 phosphate led to this investigation of the anti-tumor and anti-vascular effects of a close structural analog, combretastatin A-1 phosphate. This compound caused identical disruption of the tubulin cytoskeleton in HUVECs in vitro at similar concentrations and duration of exposure as combretastatin A-4 phosphate. Treatment of a well-vascularised murine colon adenocarcinoma (MAC 29) with an effective dose (150mg/kg) of combretastatin A-1 phosphate resulted in a dramatic decrease in functional vascular volume 2 hours after administration. Vascular shutdown was complete within 4 hours after treatment apart from in small areas of the tumor periphery. Morphological examination of hepatic deposits of HT29 and DLD-1 human colon tumors in nude mice demonstrated that combretastatin A-1 phosphate displays greater anti-tumor effects than the A-4 analog at the same dose and this order of activity (A-1>A-4) is mirrored in the subcutaneous site with the same tumor type. In summary, combretastatin A-1 phosphate can exert its anti-tumor action via an anti-vascular mechanism. The results indicate that, despite having similar in vitro anti-tubulin properties, combretastatin A-1 phosphate seems to have greater in vivo anti-tumor activity than combretastatin A-4 phosphate at the same doses and may therefore be more successful in the clinic.

Original languageEnglish (US)
Pages (from-to)3933-3940
Number of pages8
JournalAnticancer Research
Volume22
Issue number6 C
StatePublished - Nov 2002

Fingerprint

Tubulin
Blood Vessels
Phosphates
Neoplasms
Combretum
Combretaceae
Colon
combretastatin A-1
Medicinal Plants
Cytoskeleton
Nude Mice
Microtubules
Adenocarcinoma
Necrosis
Clinical Trials
Liver
fosbretabulin

Keywords

  • Anti-tumor
  • Anti-vascular
  • Combretastatin
  • Metastasis
  • Murine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Holwell, S. E., Cooper, P. A., Thompson, M. J., Pettit, G., Lippert, J. W., Martin, S. W., & Bibby, M. C. (2002). Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Research, 22(6 C), 3933-3940.

Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. / Holwell, S. E.; Cooper, P. A.; Thompson, M. J.; Pettit, George; Lippert, J. W.; Martin, S. W.; Bibby, M. C.

In: Anticancer Research, Vol. 22, No. 6 C, 11.2002, p. 3933-3940.

Research output: Contribution to journalArticle

Holwell, SE, Cooper, PA, Thompson, MJ, Pettit, G, Lippert, JW, Martin, SW & Bibby, MC 2002, 'Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate', Anticancer Research, vol. 22, no. 6 C, pp. 3933-3940.
Holwell SE, Cooper PA, Thompson MJ, Pettit G, Lippert JW, Martin SW et al. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Research. 2002 Nov;22(6 C):3933-3940.
Holwell, S. E. ; Cooper, P. A. ; Thompson, M. J. ; Pettit, George ; Lippert, J. W. ; Martin, S. W. ; Bibby, M. C. / Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. In: Anticancer Research. 2002 ; Vol. 22, No. 6 C. pp. 3933-3940.
@article{14254056311b4712a8fd6c1024640f0c,
title = "Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate",
abstract = "The combretastatins are derived from an African medicinal plant Combretum caffrum (Combretaceae). They have previously been shown to be potent inhibitors of microtubule assembly that cause marked haemorrhagic necrosis in murine subcutaneous tumors. Promising clinical trial results with combretastatin A-4 phosphate led to this investigation of the anti-tumor and anti-vascular effects of a close structural analog, combretastatin A-1 phosphate. This compound caused identical disruption of the tubulin cytoskeleton in HUVECs in vitro at similar concentrations and duration of exposure as combretastatin A-4 phosphate. Treatment of a well-vascularised murine colon adenocarcinoma (MAC 29) with an effective dose (150mg/kg) of combretastatin A-1 phosphate resulted in a dramatic decrease in functional vascular volume 2 hours after administration. Vascular shutdown was complete within 4 hours after treatment apart from in small areas of the tumor periphery. Morphological examination of hepatic deposits of HT29 and DLD-1 human colon tumors in nude mice demonstrated that combretastatin A-1 phosphate displays greater anti-tumor effects than the A-4 analog at the same dose and this order of activity (A-1>A-4) is mirrored in the subcutaneous site with the same tumor type. In summary, combretastatin A-1 phosphate can exert its anti-tumor action via an anti-vascular mechanism. The results indicate that, despite having similar in vitro anti-tubulin properties, combretastatin A-1 phosphate seems to have greater in vivo anti-tumor activity than combretastatin A-4 phosphate at the same doses and may therefore be more successful in the clinic.",
keywords = "Anti-tumor, Anti-vascular, Combretastatin, Metastasis, Murine",
author = "Holwell, {S. E.} and Cooper, {P. A.} and Thompson, {M. J.} and George Pettit and Lippert, {J. W.} and Martin, {S. W.} and Bibby, {M. C.}",
year = "2002",
month = "11",
language = "English (US)",
volume = "22",
pages = "3933--3940",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate

AU - Holwell, S. E.

AU - Cooper, P. A.

AU - Thompson, M. J.

AU - Pettit, George

AU - Lippert, J. W.

AU - Martin, S. W.

AU - Bibby, M. C.

PY - 2002/11

Y1 - 2002/11

N2 - The combretastatins are derived from an African medicinal plant Combretum caffrum (Combretaceae). They have previously been shown to be potent inhibitors of microtubule assembly that cause marked haemorrhagic necrosis in murine subcutaneous tumors. Promising clinical trial results with combretastatin A-4 phosphate led to this investigation of the anti-tumor and anti-vascular effects of a close structural analog, combretastatin A-1 phosphate. This compound caused identical disruption of the tubulin cytoskeleton in HUVECs in vitro at similar concentrations and duration of exposure as combretastatin A-4 phosphate. Treatment of a well-vascularised murine colon adenocarcinoma (MAC 29) with an effective dose (150mg/kg) of combretastatin A-1 phosphate resulted in a dramatic decrease in functional vascular volume 2 hours after administration. Vascular shutdown was complete within 4 hours after treatment apart from in small areas of the tumor periphery. Morphological examination of hepatic deposits of HT29 and DLD-1 human colon tumors in nude mice demonstrated that combretastatin A-1 phosphate displays greater anti-tumor effects than the A-4 analog at the same dose and this order of activity (A-1>A-4) is mirrored in the subcutaneous site with the same tumor type. In summary, combretastatin A-1 phosphate can exert its anti-tumor action via an anti-vascular mechanism. The results indicate that, despite having similar in vitro anti-tubulin properties, combretastatin A-1 phosphate seems to have greater in vivo anti-tumor activity than combretastatin A-4 phosphate at the same doses and may therefore be more successful in the clinic.

AB - The combretastatins are derived from an African medicinal plant Combretum caffrum (Combretaceae). They have previously been shown to be potent inhibitors of microtubule assembly that cause marked haemorrhagic necrosis in murine subcutaneous tumors. Promising clinical trial results with combretastatin A-4 phosphate led to this investigation of the anti-tumor and anti-vascular effects of a close structural analog, combretastatin A-1 phosphate. This compound caused identical disruption of the tubulin cytoskeleton in HUVECs in vitro at similar concentrations and duration of exposure as combretastatin A-4 phosphate. Treatment of a well-vascularised murine colon adenocarcinoma (MAC 29) with an effective dose (150mg/kg) of combretastatin A-1 phosphate resulted in a dramatic decrease in functional vascular volume 2 hours after administration. Vascular shutdown was complete within 4 hours after treatment apart from in small areas of the tumor periphery. Morphological examination of hepatic deposits of HT29 and DLD-1 human colon tumors in nude mice demonstrated that combretastatin A-1 phosphate displays greater anti-tumor effects than the A-4 analog at the same dose and this order of activity (A-1>A-4) is mirrored in the subcutaneous site with the same tumor type. In summary, combretastatin A-1 phosphate can exert its anti-tumor action via an anti-vascular mechanism. The results indicate that, despite having similar in vitro anti-tubulin properties, combretastatin A-1 phosphate seems to have greater in vivo anti-tumor activity than combretastatin A-4 phosphate at the same doses and may therefore be more successful in the clinic.

KW - Anti-tumor

KW - Anti-vascular

KW - Combretastatin

KW - Metastasis

KW - Murine

UR - http://www.scopus.com/inward/record.url?scp=0036875993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036875993&partnerID=8YFLogxK

M3 - Article

C2 - 12553015

AN - SCOPUS:0036875993

VL - 22

SP - 3933

EP - 3940

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -